You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Demographic and clinical outcomes for intensive care patients with hVISA and VSSA bacteraemiaa

From: Clinical outcomes and molecular typing of heterogenous vancomycin-intermediate Staphylococcus aureus bacteremia in patients in intensive care units

  hVISA (n = 14) VSSA (n = 34) p value
Patient demographics    
 Median age (years) 71.4 ± 16.9 69.7 ± 12.3 0.76
 Male sex 9 (64.3) 18 (52.9) 0.47
Comorbidity    
 Chronic renal disease 5 (35.7) 13 (38.2) 0.87
 Solid organ malignancy 3 (21.4) 5 (14.7) 0.57
 Hematological malignancy 1 (7.1) 1 (2.9) 0.508
 Diabetes mellitus 4 (28.6) 14 (41.2) 0.412
 Liver cirrhosis 4 (28.6) 5 (14.7) 0.263
 Heart disease 1 (7.1) 8 (23.5) 0.186
 Chronic pulmonary disease 1 (7.1) 1 (2.9) 0.508
 Cerebrovascular accident 2 (14.3) 10 (29.4) 0.271
Primary site of infection    0.045
 Catheter-related infection 1 (7.1) 6 (17.6)  
 Pneumonia 6 (42.9) 18 (52.9)  
 Surgical wound infection 0 3 (8.8)  
 Other 0 3 (8.8)  
 Unknown 7 (50) 4 (11.8)  
CRP 147.3 ± 11.3 132.6 ± 75.6 0.62
Albumin 2.5 ± 0.5 2.5 ± 0.6 0.82
Charlson comorbidity score 2.7 ± 1.6 3.1 ± 2.1 0.307
SOFA score 8 ± 3.2 8.4 ± 4.1 0.774
Prior vancomycin therapy 5 (35.7) 10 (29.4) 0.669
Adequate antibiotics treatment 3 12 0.279
Hemodialysis 7 14 0.403
Shock after infection 4 13 0.386
Outcomes    
 In-hospital mortality 13 (92.9) 22 (64.7) 0.046
 Attributable mortality by MRSA bacteremia 6 (42.9) 14 (41.2) 0.915
 Length of stay in hospital after MRSA bacteremia (days) 32.6 ± 34.4 33.4 ± 49.3 0.96
 Length of stay in ICU after MRSA bacteremia (days) 27.7 ± 31.5 21.2 ± 45.9 0.629
 Admission days to first culture 44.5 ± 48.3 27.0 ± 20.5 0.083
  1. aAll values presented as number (%) or mean value ± SD unless otherwise indicated
  2. CRP C-reactive protein